- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00932880
Study to Evaluate the Bioavailability of the Test Formulation of Amlodipine 10 mg Tablets (Torrent Pharmaceuticals Limited) Compared to a 10 mg Dose of Norvasc® (Pfizer) in 18 Fed, Healthy Adult Subjects
July 15, 2009 updated by: Torrent Pharmaceuticals Limited
An Open-Label, Randomized, Two-Way Crossover, Single Dose Study to Evaluate the Bioavailability of the Test Formulation of Amlodipine 10 mg Tablets [Torrent Pharmaceuticals Limited,India] Compared to a 10 mg Dose of Norvasc®, [Pfizer, USA] in 18 Fed, Healthy Adult Subjects
Objective:
- The objective of this study was to compare the rate and extent of absorption of the test formulation, amlodipine besylate 10 mg tablets (Torrent Pharmaceuticals Ltd.), with that of the marketed reference product, Norvasc® 10 mg tablets (Pfizer, Inc.), when administered under fed conditions.
Study Design:
- This was an open-label, randomized, two-way crossover study in which 18 healthy subjects were scheduled to receive a single dose of each of two treatments in two assigned dosing periods. Each dose administration was separated by a minimum 14-day washout period.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Texas
-
San Antonio, Texas, United States, 78217
- CEDRA Clinical Research, LLC
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 45 years (Adult)
Accepts Healthy Volunteers
N/A
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Sex: Male/female.
- Age: 18 - 45 years.
- Volunteer with BMI of 18-27 kg/m2 with minimum of 50 kg weight.
- With minimum blood pressure of 110/75 mmHg.
- Healthy and willing to participate in the study.
- Signed Written Informed Consent for Screening and study.
- Medical case history, physical examination, vital signs, laboratory tests and ECG without significant deviations.
- Negative drug of abuse screening test.
- Non-smokers or smoking less than 10 cigarettes a day and willing to break smoking in the course of the study.
- No history of medication for at least 2 weeks prior to study drug administration until study Period II completion.
Exclusion Criteria:
- Clinically relevant abnormal physical findings at the screening examination, which would interfere with the objectives of the study.
- Clinically relevant abnormalities in the results of the laboratory screening evaluation.
- Abnormal ECG.
- Habituation of tobacco necessitating uninterrupted tobacco consumption.
- Addiction to alcohol or history of any drug abuse.
- History of kidney or liver dysfunction.
- History of allergy to the test drug or any drug chemically similar to the drug under investigation.
- Administration/ Intake of any prescription or OTC medication for two weeks before the study.
- Patients suffering from any chronic illness such as arthritis, asthma etc.
- HIV, HCV, HBsAg positive volunteers.
- Opioids and cannabis positive volunteers based on urine test.
- Subjects suffering from any psychiatric (acute or chronic) illness.
- Administration of any investigational drug in the period 0 to 3 months before entry to the study.
- Intake of barbiturates or any enzyme-inducing drug in last three months.
- History of significant blood loss due to any reason, including blood donation in the past 12 weeks. The total blood loss in last 3 months including for this study will not exceed 350ml.
- History of any bleeding disorder.
- Existence of any surgical or medical condition, which, in the judgement of the clinical investigator, might interfere with the absorption, distribution, metabolism or excretion of the drug or likely to compromise the safety of volunteers.
- Serious adverse reaction or hypersensitivity to study drug or any of the excipients.
- Inability to communicate or co-operate with the investigator due to language problem, poor mental development or impaired cerebral function.
- Pregnant and nursing mother.
- Female not practicing barrier contraceptives.
- Contraindications to active or inactive ingredients of the formulation.
- Volunteers leaving to go on a holiday.
- Imminent reassignment of job location.
- Inadequate motivation.
- Can not come for the follow-up visits.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Bioequivalence
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Registration Dates
First Submitted
July 1, 2009
First Submitted That Met QC Criteria
July 2, 2009
First Posted (Estimate)
July 3, 2009
Study Record Updates
Last Update Posted (Estimate)
July 16, 2009
Last Update Submitted That Met QC Criteria
July 15, 2009
Last Verified
July 1, 2009
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 20-061-SA
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Norvasc
-
Chong Kun Dang PharmaceuticalCompleted
-
Conjupro Biotherapeutics, Inc.CSPC Ouyi Pharmaceutical Co., Ltd.Completed
-
Chong Kun Dang PharmaceuticalCompleted
-
Shin Poong Pharmaceutical Co. Ltd.CompletedEssential HypertensionKorea, Republic of
-
HK inno.N CorporationUnknownEssential HypertensionKorea, Republic of
-
University of Roma La SapienzaUnknown
-
Ayub Teaching HospitalKhyber Medical University PeshawarCompletedHypertension | Hypercholesterolemia | Cholesterol Deposition
-
Pfizer's Upjohn has merged with Mylan to form Viatris...CompletedHypertension
-
Torrent Pharmaceuticals LimitedCompleted
-
University of Campinas, BrazilFundação de Amparo à Pesquisa do Estado de São PauloCompletedIron Overload | ThalassemiaBrazil